Arbutus Biopharma
ABUS
ABUS
167 hedge funds and large institutions have $390M invested in Arbutus Biopharma in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
3.45% more ownership
Funds ownership: 54.92% → 58.38% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 52
Holders
167
Holding in Top 10
5
Calls
$3.1M
Puts
$2.26M
Top Buyers
| 1 | +$8.55M | |
| 2 | +$5.88M | |
| 3 | +$5.39M | |
| 4 |
Morgan Stanley
New York
|
+$4.21M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.53M |
Top Sellers
| 1 | -$2.31M | |
| 2 | -$1.25M | |
| 3 | -$596K | |
| 4 |
Squarepoint
New York
|
-$561K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$517K |